Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a light zap in the nose stop deadly ICU infections?

NCT ID NCT06867458

Prevention Sponsor: Fraser Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new method to prevent serious lung and bloodstream infections in intensive care unit (ICU) patients. The treatment uses a special light and a blue dye to kill germs in the nose. Researchers enrolled 227 adults in the ICU and checked if the procedure was practical and reduced infection rates. The goal was to gather information for a larger, more definitive study.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

227 people

The number who actually took part.

Started

Mar 2025

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All ICU patients 19 years and above * Expected length of ICU stay \>48 hrs Exclusion Criteria: * Pregnant/breastfeeding individuals * Allergy to methylene blue and/or chlorhexidine gluconate, or unknown allergy status * Nasal or facial trauma that limits access to the nose * Inability for the patients to tolerate or comply with treatment, as determined by their treating physician * Patient, TSDM or MRP declines participation * Co-enrolment with other research studies will be considered in an individual basis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hospital-acquired infections are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Healthcare-Associated Pneumonia Pneumonia, Ventilator-Associated nosocomial infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hospital-acquired infections Hospital-acquired pneumonia Nasal decolonization of staphylococcus aureus Ventilator acquired pneumonia

Contacts and locations

Locations

  • Royal Columbian Hospital

    New Westminster, British Columbia, V3L 3W7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.